Urology Medical News about benign prostatic hyperplasia

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pharmacological treatment of benign prostatic hyperplasia
Der Urologe, 10/29/09

Oelke M et al. – The combination of an [alpha]–blocker plus a muscarinic receptor antagonist is more effective than single drugs used alone. Especially in men with larger prostates, 5?–reductase inhibitors can decrease LUTS and the probability of acute urinary retention as well as need for prostate surgery. The combination of ?–blocker plus 5?–reductase inhibitor can reduce LUTS and disease progression more effectively than single drugs.

<< Previous
ABO-Incompatible Kidney Transplantation

Next >>
The role of tumor volume on outcome in prostate cancer after...

Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia
The Prostate, 11/18/09 Relevance Score: 82%

Resistive Index: A Newly Identified Predictor of Outcome of Transurethral Prostatectomy in Patients With Benign Prostatic Hyperplasia
Urology, 11/12/09 Relevance Score: 82%

Differences in Initial Benign Prostatic Hyperplasia Management Between Primary Care Physicians and Urologists
The Journal of Urology, 11/02/09 Relevance Score: 81%

Stone Formation in Prostatic Urethra After Potassium-Titanyl-Phosphate Laser Ablation of the Prostate for Benign Prostatic Hyperplasia
Journal of Endourology, 10/13/09 Relevance Score: 80%

Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing world
Indian Journal of Urology, 10/08/09 Relevance Score: 80%